Dr Kevin Fernando looks forward to Guidelines Live 2022, at which diabetes experts will unpick the latest diabetes guidance
In March 2022, NICE finally updated NICE Guideline (NG) 28,Type 2 diabetes in adults: management.1 I was delighted to see that the updated guidance has positioned sodium–glucose co-transporter-2 inhibitors (SGLT-2is) in the vanguard of oral diabetes therapies, a move driven by their renal and cardiovascular (CV) benefits, as well as by their potent glucose-lowering effects and secondary benefits on weight reduction.
NICE now recommends early combination therapy with metformin and an SGLT-2i for people with type 2 diabetes and:1,2
- chronic heart failure and atherosclerotic cardiovascular disease (ASCVD)
- who are at high risk of CV disease (a QRISK2 score of 10% or higher).
However, no drug is without harm, and we must be aware of the risk–benefit ratio of SGLT-2is to avoid potential side effects, such as diabetic ketoacidosis.
In contrast to the placement of SGLT-2is, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remain a third-/fourth-line option for people living with type 2 diabetes.1,2 I feel that this is a retrograde step, given the potent glucose-lowering properties of GLP-1 RAs, in addition to their secondary benefits on weight reduction and outcomes of ASCVD. The placement of GLP-1 RAs was based on their lack of cost effectiveness in people with type 2 diabetes and at high risk of, or with established, CV disease, and the guideline states: ‘The committee did not look at clinical- and cost-effectiveness evidence for the use of GLP-1 mimetics to control blood glucose levels.’1
This is why clinicians should consider guidelines to be handrails rather than train tracks, and have the confidence to deviate from guidance when we feel that it may benefit the patient to do so. One size does not fit all in type 2 diabetes management and, as always, we must treat the person and not the condition.
Join our primary care diabetes experts in the Diabetes Stream at Guidelines Live 2022 to discuss how we can implement NG28 in primary care in an evidence-informed yet person-centred manner, to help improve both the quality and quantity of life of people living with type 2 diabetes.
New speaker confirmed
Dr Steve Holmes
Tuesday 22 November
A focus on spirometry for the diagnosis of asthma and chronic obstructive pulmonary disease
- NICE. Type 2 diabetes in adults: management. NICE, 2015 (last updated March 2022). Available at: www.nice.org.uk/ng28
- NICE. Type 2 diabetes in adults: management. Visual summary—choosing medicines for first-line and further treatment. NICE, 2015 (last updated March 2022). Available at: www.nice.org.uk/guidance/ng28/resources/visual-summary-full-version-choosing-medicines-for-firstline-and-further-treatment-pdf-10956472093